
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve
2020; Massachusetts Medical Society; Volume: 383; Issue: 22 Linguagem: Inglês
10.1056/nejmoa2029603
ISSN1533-4406
AutoresHélio Penna Guimarães, Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Idelzuíta Leandro Liporace, Roney Orismar Sampaio, Flávio Tarasoutchi, Conrado R. Hoffmann-Filho, Rodrigo de Lemos Soares Patriota, Tiago Luiz Luz Leiria, Diana Lamprea, Dalton Bertolim Précoma, Fernando Antibas Atik, Fábio Serra Silveira, Fabio R. Farias, Diogo O. Barreto, Adail Paixão Almeida, Alexandre Cabral Zilli, João David de Souza Neto, Margaret Assad Cavalcante, Fernando A.M.S. Figueira, Flávia Cristina Soares Kojima, Lucas Petri Damiani, Renato Hideo Nakagawa Santos, Nanci Valeis, Viviane Bezerra Campos, José Francisco Kerr Saraiva, Francisco Antônio Helfenstein Fonseca, Ibraim Pinto, Carlos Costa Magalhães, João Fernando Monteiro Ferreira, John H. Alexander, Ricardo Pavanello, Alexandre Biasi Cavalcanti, Otávio Berwanger,
Tópico(s)Cardiac Arrhythmias and Treatments
ResumoThe effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain.
Referência(s)